Internationaal schreef op 18 maart 2014 15:59:
Dankje Guus voor je verwelkoming. Het was niet als kritiek bedoeld. Alleen als aanknopingspunt om wat meer achtergrond te bieden. Ik zal hieronder wat citaten toevoegen om mijn vorige post te staven:
""""............. Ruconest(Recombinant Human C1 Esterase Inhibitor) is for treatment of acute attacks of Hereditary Angioedema. Santarus believes Ruconest could be a best in class product to treat HAE and I agree after seeing the recent phase 3 results. The company plans to submit the NDA in 2013. While this product should do well in the market place I think the real potential lies outside of this indication. At a recent investor conference, Proehl stated that the company plans to initiate a proof of concept study for Ruconest to treat acute pancreatitis, a disease that affects 250,000 people in the U.S. alone. Patients who suffer from this, experience extreme pain in the abdomen which can last for several days requiring hospitalization and in severe cases death. There are no disease modifying therapies available so patients are treated with pain medications, IV fluids or surgery. If the proof of concept study has a positive outcome the potential value Ruconest could bring to the table is astronomical...............""""
jurpsy @ 08-02-2014 11:30:16 (http://www.ErikErik.com / Pharming)
The activation of the complement cascade can cause damage to cells, therefore the inhibition of the complement cascade can work as a medicine in certain conditions.[12] When someone has a heart attack, for instance, the lack of oxygen in heart cells causes necrosis in heart cells: Dying heart cells spill their contents in the extracellular environment, which triggers the complement cascade. Activation of the complement cascade attracts phagocytes that leak peroxide and other reagents, which may increase the damage for the surviving heart cells. Inhibition of the complement cascade can decrease this damage.
A recombinant C1 inhibitor obtained from the milk of transgenic rabbits, conestat alfa (trade name Ruconest)…….
Complement inhibition by C1-inhibitor has been
shown to reduce myocardial ischaemia–reperfusion injury
in animal models. We therefore studied the effects of
intravenous C1-inhibitor, following reperfusion therapy, in
patients with acute myocardial infarction.
Continuous 48-h treatment with C1-inhibitor
provides safe and effective inhibition of complement acti-
vation after reperfused acute myocardial infarction and
may reduce myocardial injury.
(Eur Heart J, 2002; 23: 1670–1677, doi:10.1053/euhj.2002.3191)
2002 Published by Elsevier Science Ltd on behalf of
The European Society of Cardiology
(http://eurheartj.oxfordjournals.org/content/23/21/1670.full.pdf)
This form of recombinant C1-inhibitor also has been given orphan drug status for delayed graft function following organ transplantation and for capillary leakage syndrome.
^ Bernstein JA (January 2008). "Hereditary angioedema: a current state-of-the-art review, VIII: current status of emerging therapies". Ann. Allergy Asthma Immunol. 100 (1 Suppl 2): S41–6. doi:10.1016/S1081-1206(10)60585-6
. PMID 18220151
en.wikipedia.org/wiki/C1-inhibitor#ci...De eerste samenwerking betreft de gezamenlijke ontwikkeling van een C1-inhibitor. Het eerste nieuwe product waarmee de partijen gezamenlijk aan de slag gaan is Factor VIII, gericht op hemofilie A. Bij beide zal SIPI de pre-klinische ontwikkeling en productie ontwikkeling financieren.
"Deze gezamenlijke productontwikkeling met SIPI, gericht op de ontwikkeling van nieuwe 'recombinante' producten op een kostenefficiente manier, is een significante strategische prestatie en zal de toekomstige groei van Pharming opstuwen", zegt Sijmen de Vries, chief executive van Pharming.
www.rtlnieuws.nl/economie/home/pharmi...